Cargando…

Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients

Detalles Bibliográficos
Autores principales:	Schneble, Erika J, Berry, John S, Trappey, Alfred F, Vreeland, Timothy J, Hale, Diane F, Sears, Alan K, Clifton, Guy T, Ponniah, Sathibalan, Shumway, Nathan M, Mittendorf, Elizabeth A, Peoples, George E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990994/ http://dx.doi.org/10.1186/2051-1426-1-S1-P236

Ejemplares similares

Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
por: Berry, John S, et al.
Publicado: (2013)

Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
por: Greene, Julia, et al.
Publicado: (2014)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
por: Jackson, Doreen, et al.
Publicado: (2015)

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development
por: Berry, JS, et al.
Publicado: (2017)

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
por: Mittendorf, Elizabeth A., et al.
Publicado: (2016)

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation
por: Berry, John S, et al.
Publicado: (2016)

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
por: Jackson, Doreen O., et al.
Publicado: (2016)

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
por: Brown, Tommy A., et al.
Publicado: (2020)

ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination
por: Adams, Alexandra M., et al.
Publicado: (2021)

Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients
por: Jackson, Doreen, et al.
Publicado: (2015)

Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and Outcomes
por: Vreeland, Timothy J, et al.
Publicado: (2017)

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
por: McCarthy, Patrick M., et al.
Publicado: (2023)

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
por: Brown, Tommy A., et al.
Publicado: (2019)

Future Directions for Monitoring Treatment Responses in Breast Cancer
por: Shupe, Matthew P., et al.
Publicado: (2014)

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
por: O’Shea, Anne E., et al.
Publicado: (2021)

Future Directions for the Early Detection of Recurrent Breast Cancer
por: Schneble, Erika J., et al.
Publicado: (2014)

Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement
por: Kemp Bohan, Phillip M., et al.
Publicado: (2020)

Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence
por: Schneble, Erika J., et al.
Publicado: (2014)

Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer
por: Graham, Lindsey J., et al.
Publicado: (2014)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
por: Vreeland, Timothy J., et al.
Publicado: (2021)

Using Technology to Maintain the Education of Residents During the COVID-19 Pandemic
por: Chick, Robert Connor, et al.
Publicado: (2020)

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis
por: Chick, Robert C., et al.
Publicado: (2021)

Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 Pandemic
por: Carpenter, Elizabeth L., et al.
Publicado: (2022)

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
por: Adams, Alexandra M., et al.
Publicado: (2022)

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
por: Anastasopoulou, Eleftheria A, et al.
Publicado: (2015)

Chemoprevention in familial adenomatous polyposis: past, present and future
por: Kemp Bohan, Phillip M., et al.
Publicado: (2020)

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
por: Carpenter, Elizabeth Lee, et al.
Publicado: (2023)

Therapeutic cancer vaccines revamping: technology advancements and pitfalls
por: Antonarelli, G., et al.
Publicado: (2021)

Vaccination of children with a live-attenuated, intranasal influenza vaccine – analysis and evaluation through a Health Technology Assessment
por: Andersohn, Frank, et al.
Publicado: (2014)

RNA Vaccines in Cancer Treatment
por: Bringmann, Anita, et al.
Publicado: (2010)

Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis
por: Meenakshisundaram, Ramachandran, et al.
Publicado: (2020)

Childhood Immunization Schedule for National Immunization Program Vaccines — China (Version 2021)
por: National Health Commission of the People’s Republic of China,
Publicado: (2021)

Promise of cancer stem cell vaccine
por: Zhou, Li, et al.
Publicado: (2015)

Development of Therapeutic Vaccines for Ovarian Cancer
por: Chow, Stephanie, et al.
Publicado: (2020)

Dendritic Cell Vaccines in Ovarian Cancer
por: Zhang, Xi, et al.
Publicado: (2021)

A Viral Nanoparticle with Dual Function as an Anthrax Antitoxin and Vaccine
por: Manayani, Darly J, et al.
Publicado: (2007)

Development and Application of Cancer Stem Cell-Targeted Vaccine in Cancer Immunotherapy
por: Lin, Ming, et al.
Publicado: (2017)

Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer
por: Hathaway, Cassandra A., et al.
Publicado: (2022)

Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
por: McCarthy, Patrick M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eoerm5knho123mg77cqu8pn450